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SUMMARY
Co-treatment of mice infected with different strains of Leishmania donovaniwith a non-ionic surfactant vesicle formulation
of buthionine sulfoximine (BSO-NIV), and sodium stibogluconate (SSG), did not alter indicators of Th1 or Th2 responses
but did result in a significant strain-independent up-regulation of IL6 and nitrite levels by stimulated splenocytes from
treated mice compared to controls. The efficacy of BSO-NIV/SSG treatment was dependent on the host being able to
mount a respiratory burst indicating that macrophages are important in controlling the outcome of treatment. In vitro
studies showed that SSG resistance was associated with a greater resistance to killing by activated macrophages, treatment
with hydrogen peroxide or potassium antimony tartrate. Longitudinal studies showed that a SSG resistant (SSG-R) strain
was more virulent than a SSG susceptible (SSG-S) strain, resulting in significantly higher parasite burdens by 4 months
post-infection. These results indicate that SSG exposure may favour the emergence of more virulent strains.
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INTRODUCTION
The level of intracellular glutathione (GSH) can
have a major impact on a number of macrophage
cellular responses. For example, it can influence a
macrophage’s ability to protect against oxidative
stress, it can control gene transcription (Haddad,
2002, Haddad, Saade and Sfieh-Garabedian, 2002),
it can influence cytokine and nitrite production, and
the type of T helper (Th) responses they promote
in vivo (Murata et al. 2002). Buthionine sulfoximine
(BSO) is a specific irreversible inhibitor of gamma
glutamyl cysteine synthetase, the enzyme which
catalyses the rate-limiting step in GSH synthesis
(Bailey, 1998). We have shown that combined treat-
ment with a non-ionic surfactant vesicular (NIV)
formulation of BSO and sodium stibogluconate
(SSG) is more effective than treatment with SSG
alone in an in vivo murine model of visceral leish-
maniasis (VL, Carter et al. 2003), indicating that
GSH can influence the therapeutic efficacy of SSG.
This is not unexpected since previous workers
have shown that thiols are important in resistance to
heavy metal drugs (Grondin et al. 1997; Legare et al.
1997; Haimeur and Ouellette, 1998) and various
mechanisms have been proposed to explain their
role. GSH alone, or the parasite-specific thiol
trypanothione alone (TSH, Wyllie, Cunningham
and Fairlamb, 2004), or a complex of the two, may
directly conjugate to heavy metals such as antimony
before they are exported from the host/parasite cell
(Haimeur and Ouellette, 1998) so that the level of
GSH or TSH (Leishmania) would therefore impact
on drug efflux from the host and/or parasite cell.
However, GSH could also act indirectly by influen-
cing the host’s immune response. Intracellular GSH
levels can control cytokine and nitrite profiles of
stimulated macrophages and therefore influence the
in vivo balance of Th1/Th2 responses (Murata et al.
2002). The outcome of antimonial drug treatment
in VL is dependent on the host having a fully
competent immune response and both Th1 and Th2
parasite-specific immune responses are required
for antimonial therapy to be fully effective (Murray
and Delph-Etienne, 2000).
Therefore in this study the role of host immune
responses in controlling the susceptibility of SSG-R
and SSG-S strains of L. donovani to BSO-NIV/SSG
treatment was determined. In addition, the suscep-
tibility of SSG-S and SSG-R strains to potassium
antimony tartrate (trivalent antimony, SbIII) was
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also determined in vitro and in vivo to ascertain
whether it correlated to susceptibility to SSG
(pentavalent antimony, SbV).
MATERIALS AND METHODS
Materials
SSG was provided by Glaxo-Wellcome (31.7% Sbv
w/w). Potassium antimony tartrate hydrate (PAT,
37.47% SbIII w/w) was obtained from Sigma-
Aldrich (Poole, UK). The non-ionic surfactant
tetraethylene glycol mono-n-hexadecylether was
purchased from Chesham Chemicals Ltd, UK.
L-buthionine sulfoximine-[S, R]-sulfoximine (BSO)
was obtained from Sigma-Aldrich (Poole, UK)
and used within 6 months of purchase. Capture
and detection anti-cytokine antibodies, IL4, IL6,
IFN c and IL12 standards and alkaline phosphatase
conjugate were obtained from PharMingen and
supplied by Insight Biotechnology (Wembley, UK).
All other reagents were of analytical grade.
Animals and parasites
Age and sex matched BALB/c mice (20–25 g,
in-house male or female) bred at University of
Strathclyde were used in this study. In addition
respiratory-burst deficient gp91phoxx/x (X-linked
granulomatous disease [X-CGD]) male mice with
a targeted disruption of the gp91phox subunit of
the NADPH-oxidase complex [phox, Cornell Uni-
versity, USA, (Murray and Nathan, 1999) provided
by Cornell University and normal C57BL/6 mice
(JacksonLaboratories, USA)were used in this study.
Commercially obtained Golden Syrian hamsters
(Mesocricetus auratus) were used for maintenance of
L. donovani strains (Harlan Olac, Bicester, UK;
Harlan, Indianapolis, USA). L. donovani strains
200011 (SSG resistant, SSG-R1), 200015 (SSG re-
sistant, SSG-R2) and 200016 (SSG susceptible,
SSG-S), which were clinically derived from patients
in India and collected under the regulations of Bihar
University Ethical Committee (Carter et al. 2001)
were used in studies performed at the University of
Strathclyde. L. donovani strain 1S (SSG-S1,Murray
and Nathan, 1999, was used in studies carried out
at Weill Medical College. Mice were infected by
intravenous injection (tail vein, no anaesthetic) with
1–2r107 L. donovani amastigotes (Carter et al.
1988). The day of parasite administration to the
mice was designated day 0 of the experiment. Animal
experiments were carried out in accordance with
UK Home Office regulations or Weill College
IACUC regulations.
Vesicle formulations
Vesicle constituents (600 mmol), consisting of 3 : 3 : 1
molar ratio of mono-n-hexadecyl ether tetraethylene
glycol, cholesterol and dicetyl phosphate were
melted by heating at 130 xC for 5 min. The molten
mixture was cooled to 70 xC, and hydrated with 5 ml
of pre-heated (70 xC) aqueous BSO (1.54 mg/ml, to
form BSO non-ionic surfactant vesicles, BSO-NIV)
or aqueous potassium antimony tartrate hydrate
(PAT, 5 mg/ml) to form PAT non-ionic surfactant
vesicles (PAT-NIV). Vesicular formulations were
homogenized at 8000¡100 rpm for 15 min at 70 xC,
using a Silverson mixer, Model L4R SU (Silverson
Machines, UK), fitted with a 5/8a tubular work
head. Vesicle suspensions were stored at room
temperature until used, usually on the day of
manufacture.
In vitro studies
Macrophage isolates from bone marrow. Bone
marrow was harvested from the femur of indi-
vidual mice by washing with 10 ml of medium
(Dulbecco’s medium supplemented with 20%
(v/v) heat-inactivated foetal calf serum, 30% (v/v)
L-cell supernatant, 100 mg/ml penicillin/strepto-
mycin and L-glutamine). The resulting cell sus-
pension was incubated in a Petri dish for 7–10
days at 37 xC in an atmosphere of 5% CO2. Cells
were harvested from the plates, pooled, pelleted
by centrifugation and resuspended in complete
medium (RPMI 1640 supplemented with 10%
(v/v) foetal calf serum and 100 mg/ml penicillin/
streptomycin and L-glutamine) and the number
of live cells determined by Trypan Blue exclusion.
Then 1–2r105 cells in 0.3 ml were added to indi-
vidual wells of a 24-well tissue culture plate, which
contained a 13 mm diameter circular glass cover-
slip. Plates were incubated at 37 xC in an atmosphere
of 5% CO2 for at least 1 h to allow macrophage
adherence.
Infection of cells. The medium was removed from
each well and replenished with 0.25 ml of fresh
complete medium (uninfected controls) or 0.25 ml
of fresh complete medium containing L. donovani
promastigotes, obtained by in vitro culture of
spleen samples from infected hamsters. Parasites
were used at a 1 : 1–1 : 10 parasite : host cell ratio and
were at least 7 days old. The cells were incubated as
before for 1–3 h, the well contents were aspirated
to remove any unattached parasites and 0.5 ml of
complete medium (controls) or complete medium
containing BSO (50–500 mM), SSG (140 mgSbv/ml),
BSO and SSG (500 mM BSO, 140 mgSbv/ml),
hydrogen peroxide (1.56–25 mM) or PAT (0.75–
3.75 mgSbIII/ml) was then added to the appropriate
wells of the plate (n=4/treatment) and the cells
were incubated for a further 72 or 96 h. In other
experiments cells were treated with 0.5 ml of com-
plete medium alone (unstimulated controls), or
completemedium containing BSO only (50–500 mM),
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IFN c/LPS (0.01–100 U IFN c/ml, 0.01–100 ng/ml
LPS) or BSO and IFN c/LPS (50–500 mM BSO,
0.01–100 U IFN c/ml, 0.01–100 ng/ml LPS) was
then added to the appropriate wells of the plate
(n=4/treatment). The contents of each well were
then transferred to individual Eppendorf tubes.
The Eppendorf tubes were stored at x20 xC until
nitrite or cytokine levels could be determined. The
wells of infected 24-well plates were washed with
PBS and then 0.2 ml of methanol was added to fix
the cells. After 2–3 min at room temperature the
methanol was removed and 0.5 ml of aqueous 10%
(v/v) Giemsa was added. After 20 min incubation
at room temperature the Giemsa was removed and
the wells washed with water. The cover-slips from
individual wells were removed, air dried, and
mounted on to glass slides. The percentage of cells
infected from 200 randomly selected cells, and
the mean number of parasites/host cell from 20
randomly selected cells, were then determined
microscopically on each cover-slip.
In vivo efficacy of drug formulations
Groups of infected mice (n=4 or 5/treatment) were
treated intravenously on day 7 with one of the fol-
lowing: PBS (controls), free SSG (equivalent to a
final dose of 70–300 mg Sbv/kg); free PAT (equiv-
alent to a final dose of 16.64 or 33.2 mg SbIII/kg) ;
PAT-NIV (equivalent to a final dose of 16.64 mg
SbIII/kg) ; BSO-NIV mixed 1 : 1 v/v with SSG sol-
ution (equivalent to a final dose of 70 mg Sbv/kg
and BSO 13.7mg/kg, BSO-NIV/SSG treatment) or
distilled water (equivalent to a final dose of BSO
13.7 mg/kg, BSO-NIV treatment. Parasite burdens
were determined on day 7 post-treatment. PAT was
used at a maximum dose of 33 mgSbIII/kg, well
below its reported LD50 of 45 mgSbIII/kg after
intravenous injection (TTECS, 2003) so that ani-
mals were not exposed to potentially toxic doses.
In some experiments, uninfected mice, age and
sex-matched with infected animals, were similarly
treated with BSO-NIV/SSG and sacrificed on
day 7 post-treatment. In studies using X-CGD mice
a lower final dose of BSO-NIV/SSG was used since
the animals were heavier. X-CGD mice and their
C57BL/6 counterparts, were treated on day 7 post-
infection with PBS (controls) or BSO-NIV mixed
1 : 1 v/v with SSG just prior to dosing (equivalent
to a final dose of 56 mg Sbv/kg and BSO 11 mg/kg).
Parasite burdens were determined on day 7 post-
treatment.
Specific antibody response of infected mice
ELISA assays were carried out to determine the
end-point titres of parasite specific IgG1 and IgG2a
using methods described by Banduwardene et al.
(1997), using horseradish peroxidase anti-mouse
IgG1 and IgG2a conjugates (1/1000 dilution,
Binding Site, UK).
Flow cytometry
The percentage of CD3+, CD45R/B220+ and
F4/80+ cells present in the spleen of control and
treated mice were determined by flow cytometry.
Briefly, single-cell suspensions were prepared from
the spleens of uninfected and infected mice in
medium (RPMI 1640 supplemented with 100 mg/ml
penicillin/streptomycin and L-glutamine, Gibco
BRL, UK). The cell suspensions were centrifuged
at 1000 g at 4 xC for 5 min and the resulting cell
pellets resuspended in 3 ml of erythrocyte lysing
solution (0.007 M ammonium chloride, 8.5 mM Tris,
pH 7.2) and incubated at 37 xC for 5 min. Cells were
washed 3 times in PBS/1% FCS and then 1r106
spleen cells were stained with 0.1–1 mg of the
appropriate anti-mouse antibody/200 ml PBS/1%
FCS (FITC-labelled anti-CD3, FITC-labelled anti-
CD45R/B220 or FITC or PE-labelled IgG isotype
controls, BD Biosciences, UK, PE-labelled F4/80,
Caltag Medsystems, UK) for 30–60 min at 4 xC.
Cells were washed 3 times in PBS/1% FCS then
resuspended in 200 ml of 0.1% formalin before
collecting data on a FACS CantoTM (BD systems).
Colour compensation was set up using BDTM
Compbeads and the antibodies used to stain
cells. Cells were gated on forward and side scatter
and the FACsDivaTM software used to analyse
results.
In vitro proliferation assays
Lymphocyte proliferation assays were carried
out using the methods described by Banduwardene
et al. (1997). Spleen cells were incubated with
medium alone (unstimulated controls), L. donovani
soluble antigen (12.5 mg/ml) or Concanavalin A
(5 mg/ml, stimulated controls) for 96 h at 37 xC in
an atmosphere of 95% air/5% CO2.
Nitrite determination
Fifty ml of the test sample (cell supernatant or
nitrite standard using doubling dilutions starting
at 100 mM) was added to a well of a 96-well ELISA
plate and 50 ml of Greiss reagent (1 : 1 v/v mixture
of 2% (w/v) sulphanilamide in 5% (v/v) orthophos-
phoric acid: 0.2% (w/v) naphthylene diamide
hydrogen chloride) added. The plate was incubated
for 5 min and the absorbance of the samples then
read at 540 nm. Nitrite levels for the samples were
determined from the standard curve obtained. The
correlation coefficient for a linear fit for the standard
data was >0.97.
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Cytokine determination
ELISA assays were carried out to determine cytokine
levels in cell supernatants using methods described
by Banduwardene et al. (1997). Cytokine levels
present in the samples were determined from the
standard curve obtained. The correlation coefficient
for a linear fit for the standard data was >0.97.
Presentation and statistical analysis of data
Parasite data from in vivo experiments were analysed
using a one-way ANOVA (using log10 transformed
parasite burden for the spleen and liver data).
Differences between treatments were then analysed
using a Fisher’s PLSD test using the Statview1
version 5.0.1 software package. Cytokine, flow cyto-
metry and nitrite data were analysed using the
non-parametric Mann Whitney U-test.
RESULTS
Combined BSO-NIV and SSG (BSO-NIV/SSG)
treatment does not preferentially induce a Th1
or Th2 response but is associated with induction of
nitrite and IL6
Consistent with previous published data single
dose treatment with 70 mg Sbv/kg SSG resulted in
a significant reduction in liver parasite burdens in
mice infected with the SSG-S strain but had no
suppressive effect on liver parasite burdens in mice
infected with the SSG-R1 strain (Table 1). In
addition, treatment with BSO-NIV significantly
reduced liver parasite burdens in mice infected
with the SSG-S strain (P<0.05), but had no sig-
nificant effect on liver parasite burdens of mice
infected with the SSG-R strain. BSO-NIV/SSG
treatment resulted in significant suppression of
liver parasite burdens for both L. donovani strains
(P<0.001, Table 1). BSO-NIV/SSG treatment also
resulted in significant reductions of splenic and
bone marrow parasite burdens (P<0.001) in mice
infected with SSG-S strain whereas similar treat-
ment of mice infected with the SSG-R1 strain
resulted in a significant increase in parasite burdens
compared with control values (Table 1).
Cytokine and nitrite levels in the supernatants
of unstimulated and ConA stimulated spleen cells
from the different groups of mice were assessed
to determine whether differences in antiparasitic
efficacy were related to alterations in cytokine and/or
nitrite production. Background and ConA stimu-
lated production of IFN c, IL4, IL10 or IL12 by
spleen cells from mice infected with either strain
and treated with PBS (controls), BSO-NIV, SSG
or BSO-NIV/SSG were similar (data not shown).
However, treatment with BSO-NIV/SSG was
consistently associated with a significant strain-
independent up-regulation in IL6 (P<0.05, Table 2)
and nitrite production by stimulated cells (P<0.01,
Table 2), indicating that this treatment enhanced
inflammatory responses in these mice. This would
be consistent with the significant increase in splenic
weights for BSO-NIV/SSG treated mice compared
to controls (mean weight, g¡S.E., SSG-S: control
0.17¡0.01; BSO-NIV/SSG 0.33¡0.01; SSG-R:
control 0.20¡0.01, BSO-NIV/SSG 0.61¡0.06).
Spleen weights for SSG treated and BSO-NIV
treated animals were similar to control values (data
not shown). The only consistent strain-dependent
effect caused by BSO-NIV/SSG treatment was
the presence of higher levels of nitrite in the super-
natants of unstimulated cells from mice infected
with the SSG-R1 strain (P<0.05, Table 2). Anti-
body levels did not indicate that any treatment was
associated with a preferential Th1 or Th2 response
since similar levels of parasite specific IgG1 and
IgG2a were present in the serum of control and
treated mice on day 14 post-infection (data not
shown).
BSO-NIV/SSG treatment is associated with an
increase in splenic F4/80+ cells but not CD3+
or CD45R/B220+ cells
Analysis of the cell populations present in the
spleens of control, BSO-NIV treated, SSG-treated
Table 1. The effect of different treatments on the
parasite burdens of mice infected with an SSG-S
or SSG-R1 Leishmania donovani strain
(Mice (4/group), infected withL. donovani strain SSG-S or
SSG-R1, were treated intravenously on day 7 post-infec-
tion with PBS (controls), free SSG (70 mgSbv/kg), BSO-
NIV (BSO 13.7 mg/kg), or BSO-NIV and SSG (final dose
BSO 13.7 mg/kg; SSG 70 mg Sbv/kg; 2r formulations
were mixed 1 : 1 immediately prior to dosing). Parasite
burdens were determined on day 14 post-infection.)
Treatment
Mean parasite burden (¡S.E.)
Spleen Liver
Bone
marrow
SSG-S Strain
Control 23¡4 1079¡188 144¡28
SSG 70 mg
Sbv/kg
35¡7 324¡110* 111¡35
BSO-NIV 37¡1 196¡71* 94¡21
BSO-NIV
and SSG
4¡1*** 4¡4*** 7¡4**
SSG-R1 Strain
Control 68¡8 3875¡428 68¡8
SSG 70 mg
Sbv/kg
50¡2 3825¡99 517¡21
BSO-NIV 65¡29 3775¡212 349¡52
BSO-NIV
and SSG
415¡135* 332¡70*** 1036¡61***
* P<0.05; ** P<0.01, *** P<0.0001 compared to
relevant control.
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or BSO-NIV/SSG treated animals infected with
L. donovani showed that none of the treatments
had any significant effect on the percentage of splenic
CD3+ or CD45R/B220+ cells present (data not
shown). BSO-NIV treatment had no significant
effect on the percentage of splenic F4/80+ cells
present compared to control values for mice infected
with either strain of L. donovani (data not shown).
In contrast, BSO-NIV/SSG treatment caused a
significant increase in the percentage of F4/80+
cells present compared with controls (P<0.001,
Fig. 1). This effect was strain independent, and
L. donovani infection-independent, since similar
results were obtained in uninfected mice and
L donovani infected mice (data not shown).
The efficacy of BSO-NIV/SSG treatment is
dependent on the ability of mice to mount a
respiratory burst
The above results indicate that activity of BSO-NIV/
SSG treatment against L. donovani is related to its
ability to induce an enhanced inflammatory response
and influx of F4/80+ cells into the spleen. Therefore
the activity of BSO-NIV/SSG was compared in
X-CGD mice, which are unable to mount a respir-
atory burst and have impaired influx of mononu-
clear cells into the liver during L. donovani infection,
Table 2. Comparison of IL-6 and nitrite production by spleen cells obtained from mice infected with
SSG-S or SSG-R1 strain of Leishmania donovani
(IL6 (ng/ml+S.E.) and nitrite (mM+S.E.) levels present in the supernatants of spleen cells obtained on day 14 from
L. donovani infected mice (strain SSG-R1 or SSG-S) mice treated with PBS (controls), SSG only (70 mgSbv/kg),
BSO-NIV alone (BSO 13.7 mg/kg) or BSO-NIV and SSG (final dose BSO 13.7 mg/kg; SSG 70 mg Sbv/kg;
2rformulations weremixed 1 : 1 immediately prior to dosing). The cells were incubated withmedium alone (unstimulated
cells) or Concanavalin A (5 mg/ml, stimulated cells) for 96 h. The results shown are from 1 of 3 separate experiments.)
Treatment Stimulus
Mean production by stimulated
spleen cells (¡S.E.)
IL-6 (ng/ml) Nitrite (mM)
Uninfected Control Medium alone 0.00¡0.00 0.27¡0.04
ConA 0.99¡0.34 1.25¡0.27.
SSG-S Control Medium alone 0.12¡0.09 0.33¡0.03
ConA 1.76¡0.40 1.18¡0.25
BSO-NIV Medium alone 0.00¡0.00 0.33¡0.04
ConA 1.99¡0.51 2.40¡0.35*
SSG Medium alone 0.00¡0.00 0.45¡0.08
ConA 1.326¡0.30 1.52¡0.14
BSO-NIV/SSG Medium alone 0.07¡0.05 0.28¡0.05
ConA 3.27¡0.16** 3.74¡0.04***
SSG-R1 Control Medium alone 0.01¡0.01 0.62¡0.16
ConA 0.97¡0.12 1.27¡0.28
BSO-NIV Medium alone 0.00¡0.00 0.58¡0.07
ConA 1.24¡0.22 1.52¡0.26
SSG Medium alone 0.02¡0.02 0.86¡0.16
ConA 1.31¡0.30 1.46¡0.31
BSO-NIV/SSG Medium alone 0.56¡0.21 2.62¡0.40**
ConA 3.66¡0.39** 5.53¡0.26***
* P<0.05, ** P<0.01, *** P<0.001 compared with corresponding controls.
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Fig. 1. The effect of different treatments on the
percentage of F4/80+ cells present in the spleen of
Leishmania donovani (strain SSG-R1). Spleen cells
(5r105/sample) from control, SSG (70 mgSbv/kg) or
SSG/BSO-NIV (SSG, 70 mgSbv/kg; BSO 13.7 mg/kg)
treated mice (n=4) were stained with 0.5 mg of PE
labelled anti-mouse F4/80 antibody. The percentage of
positive cells was determined using a FACSCantoTM
and FACsDivaTM software. Compared to control data,
***P<0.001. The results are representative of 4 separate
experiments.
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and their normal counterparts. BSO-NIV/SSG
treatment had no significant effect on splenic para-
site burdens of infected X-CGD mice compared
to its control nor did it result in a significant in-
crease in splenic weight. In contrast, similar treat-
ment of their normal counterparts with BSO-NIV/
SSG resulted in a significant reduction inL. donovani
spleen parasite numbers (P<0.01, Fig. 2) and was
associated with a significant increase in spleen weight
(P<0.02) compared to its corresponding control
(data not shown). BSO-NIV/SSG treatment caused
a similar reduction in liver parasite burdens in both
types of mice (P<0.001, Fig. 2).
SSG resistance is related to the ability to withstand
exposure to BSO, activated macrophages, hydrogen
peroxide and potassium antimony tartrate
Treatment with the highest BSO dose (500 mM)
resulted in a significant reduction in parasite num-
bers in macrophages infected with the SSG-S strain
of L. donovani (P<0.05) but had no effect on the
survival of the SSG-R1 strain (Fig. 3). BSO treat-
ment was not associated with the induction of nitric
oxide since similar levels of nitrite were present in
the supernatants of control and BSO treated cells
(data not shown).
IFN c/LPS treatment of infected macrophages
had a dose-dependent suppressive effect on L. dono-
vani parasite burdens in infected macrophages
(Fig. 4). High dose treatment (100 U IFN c/ml:
100 ng/ml LPS) resulted in a similar reduction
in parasite numbers for both strains (>97%
suppression compared to relevant controls). How-
ever, at lower levels of stimulation (<10 U IFN
c/ml: 10 ng/ml LPS) the SSG-R1 strain was sig-
nificantly more resistant to the macrophage’s anti-
leishmanial killing mechanisms (P<0.01, Fig. 4).
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Fig. 2. The effect of BSO-NIV/SSG treatment on the
parasite burdens of X-CGD or normal mice infected with
Leishmania donovani. Mice (n=5), normal C57BL/6 or
X-CGD, were infected with the 1S strain of L. donovani
and treated on day 7 post-infection with PBS (controls)
or BSO-NIV mixed 1 : 1 with SSG immediately prior to
injection (SSG, 56 mgSbv/g; BSO 11 mg/kg). On day 14
post-infection mice were sacrificed and the percentage
reduction in splenic and liver parasite burdens in BSO-
NIV/SSG treated mice compared to corresponding
control values determined. Compared to the relevant
control data, **P<0.01, *** P<0.001.
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Fig. 3. The effect of BSO treatment on the intracellular
survival of Leishmania donovani (strain SSG-S or SSG-
R1). Cells (1r105/well) were infected with L. donovani
promastigotes at a 1 : 10 ratio for 24 h and then treated
with medium alone (controls) or different concentrations
of BSO (50–500 mM) for 72 h. The percentage of cells
infected+S.E. is shown. *P<0.05 compared to
corresponding controls. Results are representative of 4
separate experiments.
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Fig. 4. The effect of stimulation with IFN c and LPS
on parasite burdens of cells infected with a SSG-S or
SSG-R strain of Leishmania donovani. Cells (1r105/well)
were infected with L. donovani SSG-S or SSG-R1
promastigotes at a 1 : 10 ratio for 24 h and then treated
with medium alone (controls) or different concentrations
of IFN c/LPS (IFN 5: 5U/ml IFN c : 5 ng/ml LPS;
IFN 10: 10 U/ml IFN c : 10 ng/ml LPS). After 72 h the
percentage of cells infected for each treatment was
determined. Infection with either strain resulted in
similar control parasite burdens. **P<0.01; ***P<0.001
compared to corresponding control value for the relevant
strain, aP<0.01 comparing results for the same
treatment for the two strains.
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IFN c/LPS treatment of infected macrophages
was associated with significant IL6, IL12 and nitrite
production compared to unstimulated controls at
all doses used (P<0.001, data not shown). There
was no inter-strain difference in the levels of
IL6, IL12 or nitrite produced by infected cells
treated with 100 U IFN c/100 ng/ml LPS (data not
shown). Similarly, there was no consistent inter-
strain difference in the amount of IL6, IL12 or
nitrite produced by cells stimulated with lower
doses of IFN c/LPS (5U/ml IFN c : 5 ng/ml LPS
or 10 U/ml IFN c : 10 ng/ml LPS, data not shown).
Exposure to hydrogen peroxide at doses above
3 mM resulted in a significant parasite killing in
macrophages infected with the SSG-S strain of
L. donovani (P<0.01) compared to controls. In
contrast, similar treatment with hydrogen peroxide
had no significant suppressive effect on the infection
level of cells infected with the SSG-R strain of
L. donovani (Fig. 5).
Single-dose intravenous treatment with PAT
solution at the highest dose of 33 mgSbIII/kg had
no significant effect on liver, spleen or bone marrow
parasite burdens of mice infected with any of
L. donovani strains compared to relevant controls
(data not shown). We have previously shown that
using a vesicular formulation can improve the effi-
cacy of a number of drugs. Therefore the effect of
treating mice with a vesicular formulation of PAT
was determined. Treatment with PAT-NIV caused
a significant reduction in liver (P<0.0001, Table 3)
but not splenic or bone marrow parasite burdens
of mice infected with the SSG-S strain compared
to controls. In contrast, similar treatment of mice
infected with SSG-R strains of L. donovani had no
significant effect on parasite burdens in any of
the sites surveyed (Table 3). The susceptibility to
PAT-NIV treatment mirrored the in vivo suscepti-
bility to SSG since treatment with SSG only caused
a significant reduction in liver parasite burdens
of mice infected with the SSG-S strain (P<0.01,
Table 3).
In vitro studies reflected in vivo studies in that
a SSG-S strain was more susceptible to PAT treat-
ment than a SSG-R strain of L. donovani (Fig. 6). All
doses of PAT caused a significant reduction in the
percentage of cells infected with the SSG-S strain
(P<0.01, Fig. 6) whereas none of the PAT treat-
ments had any significant effect on the percentage
of cells infected compared to controls for cells
infected with the SSG-R strain.
Antimony resistance is associated with higher
parasite virulence
In previous studies parasite burdens were deter-
mined early post-infection, usually on day 14, which
may have been too early for the oxidative stress
responses associated with L. donovani infection to
develop. Therefore parasite burdens of mice infected
with a SSG-S or a SSG-R strain of L. donovani were
compared up to 4 months post-infection. Delaying
assessment of parasite burdens until 4 months
post-infection showed that infection with the SSG-R
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Fig. 5. The effect of hydrogen peroxide treatment on
the intracellular survival of Leishmania donovani (strain
SSG-S or SSG-R1). Cells (1r105/well) were infected
with L. donovani promastigotes at a 1 : 10 ratio for 24 h
and then treated with medium alone (controls)
or different concentrations of hydrogen peroxide
(1.56–25 mM) for 72 h. The percentage of cells
infected+S.E. is shown. **P<0.01 compared to
corresponding controls. Results are representative of
4 separate experiments.
Table 3. Effect of different treatments on the
parasite burdens of mice infected with different
strains of Leishmania donovani
(Mice infected with L. donovani strain SSG-S, SSG-R1,
or SSG-R2 were treated intravenously on day 7 post-in-
fection with PBS (controls), free SSG (70 mgSbv/kg) or
PAT-NIV (17 mgSbIII/kg). Parasite burdens were deter-
mined on day 14 post-infection. The results are represen-
tative of 3 separate experiments.)
Treatment
Mean parasite burden (¡S.E.)
Spleen Liver Bone marrow
SSG-S Strain
Control 48¡5 2934¡290 374¡38
SSG 37¡8 1490¡235** 574¡68
PAT-NIV 173¡53 173¡53*** 449¡31
SSG-R1 Strain
Control 73¡28 2236¡254 484¡122
SSG 25¡4 2236¡254 336¡78
PAT-NIV 24¡2 2075¡396 251¡53
SSG-R2 Strain
Control 29¡5 1118¡84 184¡31
SSG 13¡3 1119¡82 110¡28
PAT-NIV 47¡16 1149¡113 196¡45
** P<0.01, *** P<0.0001 compared to relevant control.
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strain was associated with higher parasite burdens
compared to those of mice infected with the SSG-S
strain (Table 4; P<0.01, spleen, liver and bone
marrow). Spleen cells taken from mice infected
with either L. donovani strain at 4 months post-
infection did not respond to stimulation with speci-
fic antigen since levels of IFN c, IL10 or nitrite
produced were similar to unstimulated control
values (Table 5). Con A stimulation did induce
IL10, IFN c and nitrite production compared to
unstimulated controls, but the levels were similar for
cells isolated from mice infected with either strain
(Table 5). Higher levels of nitrite were produced
by unstimulated cells from mice infected with
the SSG-R strain in 1 experiment (P<0.05, Table 5)
but this effect was not obtained in a second exper-
iment (data not shown). Similar titres of antigen-
specific IgG1 and IgG2a antibodies were present
in the serum of mice infected with either strain
throughout the course of infection (data not shown).
DISCUSSION
The results of this study showed that spleen cells
from SSG/BSO-NIV treated mice infected with a
SSG-S or SSG-R strain of L. donovani produced
enhanced levels of IL6 and nitrite compared to
controls, whereas IL4 and IFN c production were
unaffected. Thus indicating that a treatment de-
signed to inhibit GSH production (BSO-NIV;
Haddad, 2002) whilst simultaneously exposing
mice to an antimonial drug, known to induce oxi-
dative stress (Gebel, 1997) and the production of
reactive oxygen and nitrogen species (Sudhandiran
and Shaha, 2003), induced an inflammatory response
rather than a switch in the type of T helper cell
response induced (Murata et al. 2002). The ability
of BSO-NIV/SSG treatment to induce an inflam-
matory response would be consistent with the sig-
nificant increase in the percentage of splenic F4/80+
cells caused by SSG-NIV/BSO treatment in both
uninfected and L. donovani infected mice, and
the ability of this treatment to result in a significant
increase in splenic weight found in this, and previous
studies (Carter et al. 2003). The inability of BSO-
NIV/SSG treatment to suppress L. donovani splenic
parasite burdens or cause a significant increase in
spleen weight in X-CGD mice, which are unable to
produce respiratory burst-derived reactive oxygen
intermediates (Murray and Nathan, 1999) would
indicate that host inflammatory responses play an
important role in determining the efficacy of BSO-
NIV/SSG treatment in the spleen. Similar treatment
of their normal counterparts gave the anticipated
significant reduction in splenic parasite burdens
and a significant increase in spleen weights. The
effects of BSO-NIV/SSG treatment were organ
specific since a similar increase in liver weight was
not obtained in treated animals and the anti-
leishmanial efficacy of this treatment was similar
in normal and X-CGD mice. This may be related
to the higher level of GSH present in the liver
compared to the spleen (Carter et al. 2003) being
able to protect liver cells against the inflammatory
response induced, or the presence of different cells
types in the two organs. Organ-dependent differ-
ences in immune responses have already been re-
ported in L. donovani (Engwerda and Kaye, 1999).
Results from this study confirmed the findings
of Kapoor, Sachez and Madhubala, (2000), who
showed that treatment of L. donovani infected
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Fig. 6. The effect of PAT treatment on parasite burdens
of cells infected with a SSG-S or SSG-R1 strain of
Leishmania donovani. Cells (1r105/well) were infected
with L. donovani SSG-S or SSG-R1 promastigotes at a
1 : 10 ratio for 24 h and then treated with medium alone
(controls) or different concentrations of PAT
(0.75–3.75 mgSbIII/ml). After 72 h the mean percentage
of cells infected+S.E. for each treatment was determined.
Table 4. Comparison of the parasite burdens of
mice infected with a SSG-S or SSG-R1 strain of
Leishmania donovani at different times post-infection
(Parasite burdens were determined at 1, 2 or 4 months
post-infection in the spleen, liver or bone marrow of
mice infected with either the SSG-S or SSG-R1 strain
of L. donovani. The results are representative of 3 separate
experiments.)
Treatment
Mean parasite burden (¡ S.E.)
Spleen Liver
Bone
marrow
2 months
post-infection
SSG-S 70¡20 21¡21 28¡11
SSG-R1 395¡134** 25¡16 165¡83
4 months
post-infection
SSG-S 848¡295 112¡64 252¡66
SSG-R1 3858¡613** 855¡214* 1585¡519*
* P<0.05, ** P<0.01 comparing results for both strains.
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macrophages with 5mMBSO resulted in a significant
reduction in the infectivity and the mean percentage
of cells infected. However, in the present study
BSO treatment was active against the SSG-S strain
of L. donovani at a much lower concentration
(0.5 mM). Kapoor et al. (2000) suggested that BSO
acted though the induction of nitric oxide via
the down-regulation of intracellular GSH. The re-
sults of this study showed that the antileishmanial
effects of BSO may not be reliant on nitric oxide
production since in vitro treatment of macrophages
infected with the SSG-S strain caused a significant
reduction in parasite numbers without inducing a
measurable change in nitrite production compared
to control values. GSH and TSH are involved in
a number of metabolic processes in the parasite
(Wyllie et al. 2004), and down-regulation of these
pathways by limiting thiol availability may induce
parasite death.
The results of this study showed that the SSG-R
strains were more resistant to a range of toxic com-
pounds compared to SSG-S strains. Thus in vitro
exposure to BSO, hydrogen peroxide, antimicrobial
agents produced by macrophages following stimu-
lationwith lowdoses of IFNc/LPS, or PAT, resulted
in a significantly lower reduction in the percentage
of cells infected with SSG-R compared to SSG-S
strains of L. donovani. In addition, in vivo treatment
with PAT-NIV was only effective at reducing liver
parasite burdens in mice infected with a SSG-S
strain of L. donovani. These results suggest that
SSG-R strains have inherent mechanism(s) that
can protect against toxic compounds which are
known to induce oxidative stress. This would explain
why BSO-NIV/SSG treatment is not only less
effective against SSG-R strains, but may also
account for the significant increase in splenic
parasite burdens obtained in BSO-NIV/SSG treated
mice compared to controls. Thus the increased
tolerance of the SSG-R strain, coupled with the
significant increase in splenic F4/80+ cells caused
by SSG/BSO-NIV treatment, would provide more
host cells for parasite growth. A relationship between
susceptibility to SSG and host antiparasitic immune
responses may not seem unreasonable since it is
well known that the efficacy of SSG treatment is
dependent on the host having a fully competent
immune response (Croft and Coombs, 2003). There-
fore development of mechanisms to evade the
effects of SSG treatment may also protect L. dono-
vani against host immune effectors. This would
explain the increased virulence of the SSG-R
strain compared to a SSG-S strain at 4 months
infection. Assessment of IFN c and nitrite pro-
duction, known stimulators of macrophage leish-
manial killing mechanisms (Murray and Delph-
Etienne, 2000), by spleen cells from mice infected
with either strain at 4 months post-infection did
not indicate that differences in parasite burdens
were related to a deficiency in the ability to produce
these mediators. Studies by other workers have
already shown a correlation between the ability of
L. donovani to resist oxidative stress and parasite
virulence (Goyal, Roy and Rastogi, 1996; Barr and
Gedamu, 2003).
Previous workers have suggested that activity
of SSG is dependent on the bioreduction of Sbv
to SbIII (Goodwin and Page, 1943). Implying that
treatment with SbIII would negate resistance to
Sbv. However, results from this study suggest that
this is not the case since SSG resistance correlated
with resistance to PAT indicating that SSG-R
strains were more resistant to both Sbv and SbIII
than SSG-S strains. This may not be surprising
Table 5. Comparison of IFN c, IL10 and nitrite production by
spleen cells obtained from mice infected with SSG-S or SSG-R1 strains
of Leishmania donovani
(Results for spleen cells taken frommice in Table 3. The results are representative
of 3 separate experiments.)
Treatment
Mean production by stimulated spleen cells (¡S.E.)
IFN c (ng/ml) IL-10 (ng/ml) Nitrite (mM)
4 months
post-infection
SSG-S
Control 1.82¡0.24 0.16¡0.08 7.67¡0.29
Antigen 2.43¡0.29 0.62¡0.33 6.48¡0.52
ConA 6.10¡0.21 11.51¡0.80 10.84¡0.74
SSG-R
Control 2.56¡0.58 1.50¡0.72 13.00¡2.61*
Antigen 2.61¡1.07 2.35¡0.92 12.38¡2.11*
ConA 7.50¡0.65 6.18¡2.29 8.02¡0.98
* P<0.05 comparing results for SSG-S and SSG-R1 strains using a Mann
Whitney U test.
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since previous workers have shown that L. infantum
strains selected for resistance to SbIII were cross-
resistant to Sbv (Sereno et al. 1998).
Our results do not rule out the possibility that
the increased efficacy of BSO-NIV/SSG treatment
compared to SSG alone is due to increased drug
accumulation in infected cells compared to treat-
ment with SSG alone. A reduction in GSH/TSH
availability in infected macrophages and/or in
Leishmania parasites could result in lower levels of
GSH/TSH for conjugation to GSH/TSH prior
to drug export (Legare et al. 1997). Data from our
previous study (Carter et al. 2003) showed that
combined treatment with BSO-NIV/SSG was not
associated with a significant decrease in spleen
and liver GSH levels, but rather a significant increase
in the levels of reduced GSH present in the liver
and a significant increase in the total amount of
GSH present in the spleen. However, levels were
determined at day 7 post-treatment in that study
and may not reflect GSH levels immediately after
dosing and may not be representative of the effect
of treatment on parasite-specific thiols. Wyllie et al.
(2004) demonstrated that treatment with SbIII
(promastigotes and amastigotes) or Sbv (amastigotes)
had two effects on thiol metabolism which would
make parasites more susceptible to the toxic effects
of reactive oxygen species, i.e. causing rapid efflux
of intracellular GSH and TSH on an equimolar
basis from the parasites, and accumulation of oxi-
dized GSH and TSH, probably by inhibition of
TSH reductase. Therefore, differences in the sus-
ceptibility of the L. donovani strains used in this
study may be related to inherent differences in
intracellular GSH and/or TSH levels.
In summary our results indicate that resistance
to the pentavalent antimonial drug SSG also confers
cross-resistance to trivalent antimonials. In addition
our results indicate that SSG resistant strains may
be more virulent due to an enhanced ability to tol-
erate oxidative stress.
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